Liminatus Pharma (LIMN) Stock Price, News & Analysis

Company Overview

Liminatus Pharma Inc. (NASDAQ: LIMN) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunology therapies targeting autoimmune and inflammatory disorders. The company leverages its proprietary IMMX™ platform to design small-molecule modulators that address key pathways in innate and adaptive immune responses. Liminatus’s lead candidates are engineered to offer targeted efficacy with improved safety profiles compared with existing treatment options.

Founded in 2018 as a spin-out from Massachusetts Institute of Technology research, Liminatus has assembled a multidisciplinary R&D team with deep expertise in medicinal chemistry, immunology and translational science. Its pipeline includes three programs in various stages of development: an orally administered immunomodulator for rheumatoid arthritis and inflammatory bowel disease, a second-generation compound for rare complement-mediated conditions, and a preclinical asset aimed at neurological autoimmune disorders.

The company is headquartered in Boston, Massachusetts, and maintains clinical and regulatory operations in the United States and Europe. Liminatus collaborates with leading contract research organizations and academic centers to advance its clinical studies, with ongoing Phase 1 and Phase 2 trials enrolling patients across North America and the European Union. These partnerships are designed to accelerate development timelines and expand the global reach of its therapies.

Led by President and CEO Dr. Emily Parker, formerly of Biogen’s neurology research division, and CSO Dr. Mark Reynolds, a veteran immunologist with experience at multiple biotech startups, Liminatus has secured backing from prominent venture capital firms specializing in life sciences. The company’s strategic focus on immune modulation and its robust intellectual property portfolio position it to address significant unmet needs in autoimmune and inflammatory diseases.

Key Stats

• Today's Range: $8.74 to $10.20
• 50-Day Range: N/A
• 52-Week Range: $4.40 to $33.66
• Volume: 196,150 shs
• Average Volume: 438,335 shs
• Market Capitalization: $234.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LIMN Stock Analysis - Frequently Asked Questions

How have LIMN shares performed this year?

Liminatus Pharma's stock was trading at $23.98 at the start of the year. Since then, LIMN stock has decreased by 62.4% and is now trading at $9.02.

How do I buy shares of Liminatus Pharma?

Shares of LIMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIMN
• Previous Symbol: NASDAQ:LIMN
• CIK: 1971387
• Web: liminatuspharma.com
• Phone: (213) 273-5453
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,010,000
• Free Float: N/A
• Market Cap: $234.61 million
• Optionable: N/A
• Beta: N/A